title: Number of antihypertensive drugs at 1 year after kidney transplantation.
abstract: High blood pressure (BP) affects up to 90% of kidney transplant recipients and is associated with lower patient and graft survival rates. Kidney Disease/Improving Global Outcomes (KDIGO) guidelines suggest maintaining BP at lower than 130/80 mm Hg. Multidrug therapy is usually required for the control of BP in this population. Our aim was to analyze the number of antihypertensive drugs used in our kidney transplantation population at 1 year after transplantation and their influence on graft and patient outcome. We included 411 deceased-donor kidney transplantation cases; data were obtained from a prospectively maintained institutional database. BP was measured at the outpatient clinic. Approximately 97 patients were not under antihypertensive therapy, whereas 130, 119, 52, and 13 received 1, 2, 3, or 4 antihypertensive drugs, respectively. The number of antihypertensive drugs was significantly related to lower patient survival rates independently of a previous diagnosis of hypertension and diabetes, recipient age and sex and renal function at 1-year. After multivariate linear regression analysis high body mass index, male gender of recipients, donor hypertension, previous acute rejection, and cyclosporine therapy were risk factors independently related to a higher number of antihypertensive drugs. To conclude, the number of antihypertensive drugs is an objective and easy-to-measure marker related to lower patient survival rates. Recipient body mass index, type of calcineurin inhibitor, and acute rejection are modifiable risk factors whose control can help to reduce the number of antihypertensive drugs needed to treat high BP in the kidney transplantation population.
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain. Electronic address: kislikova@gmail.com.
authors: M
authors: M
authors: Kislikova
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: M
authors: M
authors: Seras
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: E
authors: E
authors: Monfa
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: E
authors: E
authors: Rodrigo
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: G
authors: G
authors: Fernandez-Fresnedo
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: J C
authors: JC
authors: Ruiz
authors: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors: M
authors: M
authors: Arias
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D016572:Cyclosporine / Q000627:therapeutic use; D048909:Diabetes Complications / Q000150:complications; D046148:Donor Selection; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000401:mortality / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D016572:Cyclosporine